GO
GOV.F Insulet Corporation
- Market cap
- EUR 9.30B
- P/E
- 25.4x
- P/B
- 6.63x
- ROE
- 27.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GOV.F undervalued?
Graham numberGOV.F trades 173.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Insulet Corporation fundamental analysis
No fundamental analysis for Insulet Corporation yet.
Insulet Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin m…
Full company profileInsulet Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Insulet Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 367M | 464M | 564M | 738M | 904M | 1.10B | 1.31B | 1.70B | 2.07B | 2.71B | 3.21B |
| Gross Profit | 211M | 277M | 370M | 480M | 582M | 752M | 806M | 1.16B | 1.45B | 1.94B | 2.30B |
| Operating Income | -10.7M | -7.39M | 27.4M | 50.0M | 51.5M | 126M | 37.6M | 220M | 309M | 474M | 589M |
| EBITDA | - | 8.49M | 49.8M | 74.2M | 110M | 81.7M | 36.5M | 324M | 424M | 489M | 713M |
| Net Income | -28.9M | -26.8M | 3.29M | 11.6M | 6.80M | 16.8M | 4.60M | 206M | 418M | 247M | 436M |
| EPS | - | -0.46 | 0.06 | 0.19 | 0.10 | 0.24 | 0.07 | 2.95 | 5.96 | 3.51 | 6.29 |
| Balance Sheet | |||||||||||
| Total Assets | 457M | 817M | 929M | 1.14B | 1.87B | 2.05B | 2.25B | 2.59B | 3.09B | 3.19B | 3.42B |
| Total Liabilities | 393M | 658M | 717M | 1.07B | 1.27B | 1.49B | 1.77B | 1.86B | 1.88B | 1.68B | 1.84B |
| Shareholders' Equity | 63.2M | 159M | 212M | 75.9M | 604M | 556M | 476M | 733M | 1.21B | 1.52B | 1.58B |
| Cash & Short-term Investments | 137M | 273M | 114M | 214M | 907M | 792M | 675M | 704M | 953M | 716M | 584M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.9M | 41.3M | 35.9M | 98.4M | 84.0M | -68.1M | 119M | 151M | 430M | 569M | 434M |
| Capital Expenditure | 22.1M | 73.8M | 157M | 164M | 129M | 112M | 123M | 166M | 134M | 219M | 169M |
| Free Cash Flow | - | -36.0M | -126M | -72.5M | -82.5M | -191M | -38.3M | -14.8M | 296M | 350M | 265M |
| Ratios | |||||||||||
| ROE | -45.7% | -16.9% | 1.6% | 15.3% | 1.1% | 3.0% | 1.0% | 28.2% | 34.5% | 16.3% | 27.6% |
| ROA | -6.3% | -3.3% | 0.4% | 1.0% | 0.4% | 0.8% | 0.2% | 8.0% | 13.5% | 7.7% | 12.8% |
| Net Profit Margin | -7.9% | -5.8% | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% | 13.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Insulet Corporation dividends
Insulet Corporation has not paid dividends in the last 9 fiscal years.
Who owns Insulet Corporation
- Insiders 0.33%
- Institutions 99.67%
- Public & others 0.00%
- Shares outstanding 69.4M
- Free float 69.1M
Insulet Corporation company profile
- Company name
- Insulet Corporation
- Ticker
- GOV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,400
- Fiscal year end
- December
- Address
- 100 Nagog Park, Acton, MA, United States, 01720
- Phone
- 978 600 7000
- Website
- insulet.com
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corporation management
10- Ms. Ashley A. McEvoyCEO, President & Director · born 1971
- Ms. Flavia H. PeaseExecutive VP & CFO · born 1973
- Mr. Eric BenjaminExecutive VP & COO · born 1983
- Mr. John Wodick Kapples J.D.Senior VP & General Counsel · born 1960
- Mr. Prem SinghSenior Vice President of Global Operations · born 1977
- Mr. Amit GulianiSenior VP & CTO
- Ms. Clare TrachtmanVice President of Investor Relations
- Mr. Chuck MedovichSenior VP and Chief Quality, Regulatory & Compliance Officer
- Ms. Angela Geryak WiczekSenior Director of Corporate Communications
- Mr. Philip HildaleSenior Vice President of Sales & Customer Care